In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.
The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...
El Mundo on MSN23h
Drug that protects against HIV with two 'shots' a year, discovery of the year for 'Science'Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
A court ruling doesn’t permit schools to “force-vaccinate” students, it addresses civil liability for accidentally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback